Testing the Safety and Efficacy of a Novel Barrier Cream for the Treatment of Moisture Associated Skin Damage

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2026

Study Completion Date

November 1, 2026

Conditions
Moisture Associated Skin DamageIncontinence Associated DermatitisFecal Incontinence
Interventions
DRUG

Control (Standard treatment)

Patients in the control arm will be treated with a standard zinc oxide barrier cream. Scotiaderm will supply the control product, such that the formula is identical to the intervention with the only difference being the addition of plant extract in the investigational product.

OTHER

Novel Barrier Cream

Patients randomized to the intervention arm will receive treatment with Scotiaderm's proprietary barrier cream formula. This product contains soy extract for enhanced healing of MASD secondary to fecal incontinence.

All Listed Sponsors
collaborator

The Salvation Army Toronto Grace Health Centre

UNKNOWN

lead

Scotiaderm

OTHER